Do immune checkpoint inhibitors perform identically in patients with weight extremes?

Immunotherapy. 2018 Jul;10(9):733-736. doi: 10.2217/imt-2018-0053.

Abstract

The interaction between the two recent hallmarks of carcinogenesis, the immune system and energetic metabolism, has not been well investigated. The limited literature available on this topic describes a correlation between the efficacy and safety of immune checkpoint inhibitors with body mass index. A key knowledge gap is the understanding of this correlation as outcomes are strongly affected highlighting the need to prospective studies in this regard. This paper evaluates the rationale to these correlations at weight extremes and suggests the evaluation patient's weights and associated inflammatory profile before the initiation of immune checkpoint inhibition in cancer patients.

Keywords: anorexia; cachexia; immune checkpoint inhibitors; obesity.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Body Mass Index*
  • Costimulatory and Inhibitory T-Cell Receptors / immunology
  • Humans
  • Immunotherapy / methods*
  • Inflammation
  • Neoplasms / complications
  • Neoplasms / drug therapy*
  • Obesity / complications
  • Obesity / drug therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Costimulatory and Inhibitory T-Cell Receptors